2016 American Society of Clinical Oncology Annual Meeting*

Download All
June 3-7, 2016; Chicago, Illinois
Brian Rini, MD, and Daniel M. Geynisman, MD, review data from key genitourinary cancer presentations at the 2016 American Society of Clinical Oncology Annual Meeting.
Daniel M. Geynisman, MD
Brian Rini, MD, FASCO

Genitourinary Cancers

PD-L1 expression, TCGA subtype, and mutational load were independent predictors of atezolizumab response in patients with mUC, and response prediction improved significantly with combination of these markers.

Released: June 14, 2016

Nivolumab treatment beyond progression associated with reduced tumor burden, improved OS, and lower incidence of all grade adverse events in patients with advanced RCC.

Released: June 9, 2016

Atezolizumab shows rapid and durable clinical responses and a tolerable safety profile in heavily pretreated patients with metastatic urothelial carcinoma.

Released: June 6, 2016

Patient-reported outcomes from CHAARTED indicate that adding docetaxel to ADT increased physical symptoms during first 3 months of treatment but was associated with significantly improved QoL at 12 mos in patients with mHSPC.

Released: June 7, 2016

Cabazitaxel and docetaxel show similar clinical activity in mCRPC but with distinct safety profiles.

Released: June 7, 2016

Results from this small exploratory study suggest that radium-223 retreatment is well tolerated and may help delay future bone events in patients with CRPC and bone metastases who experience radiographic or clinical progression following an initial course of radium-223.

Released: June 7, 2016

Here are my thoughts on the abstracts from ASCO 2016 that have the most potential to change clinical practice.

Brian Rini, MD, FASCO Released: May 31, 2016

In this activity, Daniel M. Geynisman, MD, and Brian Rini, MD, FACP, analyze and discuss the most clinically relevant data on the management of genitourinary cancers presented at the 2016 ASCO annual meeting.

Daniel M. Geynisman, MD Brian Rini, MD, FASCO Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 12, 2016 Expired: No longer available for credit

Atezolizumab shows rapid and durable clinical responses and a tolerable safety profile in previously untreated, cisplatin-ineligible patients with advanced or metastatic urothelial carcinoma.

Released: June 6, 2016

In this downloadable slideset, Daniel M. Geynisman, MD and Brian Rini, MD, review key data presented at the 2016 annual meeting of the American Society of Clinical Oncology.

Released: August 12, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC in collaboration with Postgraduate Institute for Medicine
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue